Images List Premium Download Classic

Autoimmune Disorders

Autoimmune Disorders-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions and methods of use of phorbol esters
Biosuccess Biotech Co. Ltd.
November 09, 2017 - N°20170319533

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as hiv and aids, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune ...
Methods of treating graft versus host disease using il-2 muteins
Biosuccess Biotech Co. Ltd.
November 02, 2017 - N°20170313753

Described herein are immunosuppressive molecules including immunosuppressive variants of il-2, and use of such molecules to treat inflammatory and autoimmune disorders.
Use of levocetirizine and montelukast in the treatment of autoimmune disorders
Biosuccess Biotech Co. Ltd.
October 19, 2017 - N°20170296534

The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Autoimmune Disorders Patent Pack
Download + patent application PDFs
Autoimmune Disorders Patent Applications
Download + Autoimmune Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Modulators of retinoid-related orphan receptor gamma
Orphagen Pharmaceuticals, Inc.
September 21, 2017 - N°20170267712

Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor γ (rorγ) activity. This modulation has numerous effects, including inhibition of th-17 cell function and/or th-17 cell activity, and inhibition of re-stimulation of th-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of rorγ results in stimulation of th-17 cell function ...
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
Incyte Holdings Corporation
September 07, 2017 - N°20170253598

The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jaks) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Liquid formulation comprising gm-csf neutralizing compound
Takeda Gmbh
September 07, 2017 - N°20170252436

The present invention relates to aqueous formulations comprising a compound neutralizing gm-csf in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing gm-csf in view of long-term storage. In ...
Autoimmune Disorders Patent Pack
Download + patent application PDFs
Autoimmune Disorders Patent Applications
Download + Autoimmune Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Eluting matrix and uses thereof
The General Hospital Corporation
August 31, 2017 - N°20170246250

Cxcl12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
Incyte Holdings Corporation
August 31, 2017 - N°20170246157

The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase 1 (jak1) and are useful in the treatment of diseases related to the activity of jak1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of ...
Gemoab Monoclonals Gmbh
August 24, 2017 - N°20170240612

The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and ...
Compugen Ltd.
August 17, 2017 - N°20170232062

This invention relates to a protein c1orf32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
Forward Pharma A/s
August 17, 2017 - N°20170231943

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix ...
Controlled release pharmaceutical compositions comprising a fumaric acid ester
Forward Pharma A/s
August 17, 2017 - N°20170231941

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e. G. Psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance ...
N-terminally truncated interleukin-38
Fraunhofer-gesellschaft Zur FÖrdeung Angewandten Forschung E.v.
August 03, 2017 - N°20170218039

The present invention pertains to an n-terminally truncated interleukin (il)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated il-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that il-38 is n-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune ...
Autoimmune Disorders Patent Pack
Download + patent application PDFs
Autoimmune Disorders Patent Applications
Download + Autoimmune Disorders-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorders-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Disulfur bridge linkers for conjugation of a cell-binding molecule
Suzhou M-conj Biotech Co., Ltd.
July 27, 2017 - N°20170209595

The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of ...
Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
Board Of Regents, The University Of Texas Sytem
July 27, 2017 - N°20170209587

Provided herein are compositions and methods for preparing intraarticular formulations comprising biocompatible pharmaceutical agents and use thereof in the treatment of diseases, such as degenerative bone diseases, including osteoarthritis of the knee, hip, or other joints, and similar chronic or acute destructive arthropathies resulting from autoimmune disorders or infectious disease.
Novel compounds useful as s100-inhibitors
Active Biotech Ab
July 20, 2017 - N°20170204098

A compound of formula (i) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between s100a9 and interaction partners such as rage, tlr4 and emmprin and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
Disulfur bridge linkers for conjugation of a cell-binding molecule
Suzhou M-conj Biotech Co., Ltd.
July 20, 2017 - N°20170202975

The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of ...
Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone ...
Drk Blutspendedienst Baden-wÜrttemberg-hessen Ggmbh
July 13, 2017 - N°20170198257

The present invention pertains to an improved mesenchymal stromal cell (msc) preparation and a method for producing the same. The invention provides a new strategy to isolate msc from bone marrow mononuclear cells (bm-mncs) by pooling bm-mncs of multiple unrelated (third-party) bone marrow donors. The msc preparation manufactured in accordance with the methodology of the invention is characterized by a ...
Apoptosis signal-regulating kinase inhibitors
Drk Blutspendedienst Baden-wÜrttemberg-hessen Ggmbh
July 13, 2017 - N°20170196844

Wherein x1, x2, x3, x4, x5, x6, x7, x8, r1, r2, r3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or ...
Improved anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
Immco Diagnostics, Inc.
June 22, 2017 - N°20170176454

Provided are compositions that contain mammalian cells for use in detecting antibodies. The mammalian cells are modified such that they do not contain ledgf protein. The mammalian cells are immobilized on a solid substrate. The compositions can also contain mammalian cells that contain the ledgf protein. Methods for using the cell compositions in diagnostic approaches are included, as are kits ...
Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
Southern Research Institute
June 22, 2017 - N°20170174694

The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (lrrk2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal lrrk2 kinase activity. Compounds of the present disclosure can be used to treat disorders including ...
Loading